Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BNTC Benitec Biopharma

Closed 01-14 16:00:00 EST

12.13

-0.17

-1.38%

盘后12.00

-0.13-1.07%

18:00 EST

High12.43	Low11.97	Vol86.51K
Open12.23	D1 Closing12.30	Amplitude3.74%
Mkt Cap410.75M	Tradable Cap252.92M	Total Shares33.86M
T/O1.06M	T/O Rate0.41%	Tradable Shares20.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BNTC","market":"US","secType":"STK","nameCN":"Benitec Biopharma","latestPrice":12.13,"timestamp":1768424400000,"preClose":12.3,"halted":0,"volume":86509,"hourTrading":{"tag":"盘后","latestPrice":12,"preClose":12.13,"latestTime":"18:00 EST","volume":20386,"amount":247684.49,"timestamp":1768431614658},"delay":0,"floatShares":20850800,"shares":33862226,"eps":-1.055638,"marketStatus":"Closed","change":-0.17,"latestTime":"01-14 16:00:00 EST","open":12.23,"high":12.43,"low":11.97,"amount":1055800.042,"amplitude":0.037398,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.055638,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768467600000},"marketStatusCode":5,"adr":1,"adrRate":200,"listingDate":1439870400000,"exchange":"NASDAQ","adjPreClose":12.3,"preHourTrading":{"tag":"盘前","latestPrice":12.5461,"preClose":12.3,"latestTime":"08:58 EST","volume":22,"amount":276.002012,"timestamp":1768399139276},"postHourTrading":{"tag":"盘后","latestPrice":12,"preClose":12.13,"latestTime":"18:00 EST","volume":20386,"amount":247684.49,"timestamp":1768431614658},"volumeRatio":0.626703,"impliedVol":0.6272,"impliedVolPercentile":0.5233},"requestUrl":"/m/hq/s/BNTC","defaultTab":"news","newsList":[{"id":"2602155969","title":"Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602155969","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602155969?lang=en_us&edition=fundamental","pubTime":"2026-01-11 21:00","pubTimestamp":1768136435,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy . The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3wndQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","LU2210149790.SGD","SG9999014039.USD","LU0314104364.USD","NDAQ","BK4588","BK4139","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2602559576","title":"Benitec Biopharma Provides Positive Long-Term Clinical Study Results for Bb-301 Phase 1B/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602559576?lang=en_us&edition=fundamental","pubTime":"2026-01-11 21:00","pubTimestamp":1768136403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4JKMGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2602531478","title":"Benitec Biopharma Unveils Gene Therapy Breakthrough for OPMD-Related Dysphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2602531478","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602531478?lang=en_us&edition=fundamental","pubTime":"2026-01-11 07:50","pubTimestamp":1768089056,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. has released a new presentation detailing the development of BB-301, a genetic medicine candidate for the treatment of Oculopharyngeal Muscular Dystrophy -related dysphagia. BB-301 employs a single-vector approach that combines gene silencing of the mutant PABPN1 gene with the delivery of a functional, healthy gene. The therapy is administered directly to the pharyngeal constrictor muscles through intramuscular injection, aiming to restore normal muscle function by blocking the production of the harmful protein while supplying a new, functional version. The presentation highlights BB-301's clinical progress, including a 100% responder rate in Cohort 1 and ongoing pivotal study planning. The candidate has been granted Fast Track and Orphan Drug Designations from regulatory agencies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL8Kgtlm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2595751575","title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595751575","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595751575?lang=en_us&edition=fundamental","pubTime":"2025-12-30 08:32","pubTimestamp":1767054727,"startTime":"0","endTime":"0","summary":"Suvretta Capital Management, LLC has reported the acquisition of common shares of Benitec Biopharma Inc. , according to a recent SEC Form 4 filing. The form was filed by more than one reporting person, including Suvretta Capital Management, LLC and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5Sm03R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2593510284","title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510284","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510284?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:45","pubTimestamp":1766450739,"startTime":"0","endTime":"0","summary":"Suvretta Capital Management, LLC has reported the acquisition of common shares of Benitec Biopharma Inc. , according to a recent SEC filing. The form was filed by more than one reporting person, including Suvretta Capital Management, LLC and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLnJz19:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2588061200","title":"Benitec Biopharma Inc. held annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588061200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588061200?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:28","pubTimestamp":1764714494,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. held its 2025 Annual Meeting of Stockholders on December 1, 2025. Stockholders elected Dr. Jerel Banks and Megan Boston to the board of directors. The appointment of the independent registered public accounting firm was ratified. All proposals brought before the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL23s8v4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2585462784","title":"Benitec Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462784?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:16","pubTimestamp":1763990160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 08:16 ET (13:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"gpt_icon":0},{"id":"2584320926","title":"Benitec Biopharma Announces Pricing Of $100 Million Common Stock Offering At $13.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2584320926","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584320926?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:44","pubTimestamp":1763570644,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Benitec Biopharma Inc ::*BENITEC BIOPHARMA INC. ANNOUNCES PRICING OF $100 MILLION COMMON STOCK OFFERING*BENITEC BIOPHARMA INC - EACH SHARE OF COMMON STOCK IS BEING SOLD AT AN OFFERIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD12l9sh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2584969003","title":"Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969003?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:15","pubTimestamp":1763504124,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating on November 4. Ritu Baral has given her Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/benitec-biopharma-strong-financial-position-and-promising-clinical-developments-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/benitec-biopharma-strong-financial-position-and-promising-clinical-developments-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPA","AZTA","CPRT","CRDL","POWL","CLCO","BRBR","ANRO","BNTC","ATRA","CGON","VIPS","ATOS","AHL","CRGO","BMA","AS","TBBB","BV","ADIL","BULL","ENTA","TGT","ATKR","BZ","BBWI","DY","ARBE","NVDA","NTES","WB","ENR","ALLT","CDLR","CRNC","CLSD","AREC","EARN","DE","WMT","CING","TCOM","XP","DLB","ARMK","ZTO","ACM"],"gpt_icon":1},{"id":"2583224687","title":"Benitec Biopharma reports first quarter net loss of $9.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583224687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583224687?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:32","pubTimestamp":1763159540,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. reported no revenues for the quarter ended September 30, 2025, consistent with the same period in 2024. Total operating expenses rose to $9.8 million from $5.8 million in the prior year quarter, primarily due to higher general and administrative costs, which increased to $6.4 million from $2.2 million, while research and development expenses decreased slightly to $3.4 million from $3.6 million. The net loss attributable to shareholders was $9.0 million, or $ per basic and diluted share, compared to $5.1 million, or $ per basic and diluted share in the previous year. Cash and cash equivalents stood at $94.5 million as of September 30, 2025. In November 2025, Benitec raised approximately $100 million through a public offering of common stock. The company also reported that the FDA granted Fast Track Designation for its BB-301 candidate in Oculopharyngeal Muscular Dystrophy, following positive interim clinical study results.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLb0DPZl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2583687313","title":"Biotech firm Benitec's fiscal Q1 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583687313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583687313?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:11","pubTimestamp":1763158289,"startTime":"0","endTime":"0","summary":"Biotech firm Benitec's fiscal Q1 net loss widensOverviewBenitec fiscal Q1 net loss widens to $9 mln, with increased operating expensesCompany raised $100 mln in oversubscribed public offering to fund ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ16M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2583687193","title":"Benitec Biopharma reports Q1 EPS (22c), consensus (33c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583687193","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583687193?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:10","pubTimestamp":1763158241,"startTime":"0","endTime":"0","summary":"“We are fortunate to have achieved several important milestones this year. We previously announced positive interim clinical study results from the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-reports-q1-eps-22c-consensus-33c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-reports-q1-eps-22c-consensus-33c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"gpt_icon":0},{"id":"2583682748","title":"Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682748","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682748?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:01","pubTimestamp":1763157718,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48882522/benitec-biopharma-q1-eps-0-22-beats-0-41-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"gpt_icon":0},{"id":"2583827926","title":"BRIEF-Benitec Biopharma Q1 EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2583827926","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583827926?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157646,"startTime":"0","endTime":"0","summary":"BRIEF-Benitec Biopharma Q1 EPS USD -0.22\n\n\nNov 14 (Reuters) - Benitec Biopharma Q1 net income USD -9 million.\n\nQ1 operating income USD -8.9 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLXF4D458:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2583682731","title":"Benitec Biopharma Q1 Net Income USD -9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682731?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLXF4D458:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"2583728682","title":"Press Release: Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583728682","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583728682?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157600,"startTime":"0","endTime":"0","summary":"--Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration  review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301--. --Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301--. --First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025--. --The Company raised approximately $100 million in an oversubscribed public offering of common stock, which is expected to fund advancement of the BB-301 Oculopharyngeal Muscular Dystrophy  registrational program and associated regulatory filing activities--. HAYWARD, Calif., Nov. 14, 2025  -- Benitec Biopharma Inc.  , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary \"Silence and Replace\" DNA-directed RNA inter","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4097","BK4547","BNTC"],"gpt_icon":0},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMK","DLB","DE","CLSD","NVDA","DY","ATAI","ATRA","ACM","CRDL","ARBE","LGN","NTES","ANRO","XP","CRGO","BTBT","ZTO","ALLT","WB","ADIL","AHL","CDLR","AS","CPA","BBAR","BZ","BNZI","CING","ATKR","BV","TGT","TCOM","CRNC","CLCO","AREC","ATOS","BNTC","DEFT","BMA","AZTA","BRBR","CGON","BBWI","POWL"],"gpt_icon":1},{"id":"2582333448","title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2582333448","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582333448?lang=en_us&edition=fundamental","pubTime":"2025-11-11 10:52","pubTimestamp":1762829534,"startTime":"0","endTime":"0","summary":"Suvretta Capital Management, LLC and related entities have reported the acquisition of common shares of Benitec Biopharma Inc. , according to a recent SEC filing. Other reporting owners include Averill Madison Master Fund, Ltd., Averill Master Fund, Ltd., and Aaron Cowen, with additional reporting beneficial owners listed in the filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL21XWR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Suvretta Capital Management Reports Acquisition of Benitec Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2581858614","title":"Benitec Biopharma Inc. Files Initial Statement of Beneficial Ownership for Director Sharon Mates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581858614","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581858614?lang=en_us&edition=fundamental","pubTime":"2025-11-08 08:49","pubTimestamp":1762562972,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc. has filed an initial statement of beneficial ownership. The filing lists Sharon Mates as the beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nNDL1yK0yg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.benitec.com","stockEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.0267},{"period":"3month","weight":-0.2264},{"period":"6month","weight":0.0477},{"period":"1year","weight":0.1838},{"period":"ytd","weight":-0.0869}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.034846},{"month":2,"riseRate":0.6,"avgChangeRate":0.110018},{"month":3,"riseRate":0.8,"avgChangeRate":0.05329},{"month":4,"riseRate":0.4,"avgChangeRate":0.026049},{"month":5,"riseRate":0.4,"avgChangeRate":-0.050483},{"month":6,"riseRate":0.2,"avgChangeRate":-0.131553},{"month":7,"riseRate":0.5,"avgChangeRate":0.061416},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00465},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.108578},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.026473},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.075117},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.032403}],"exchange":"NASDAQ","name":"Benitec Biopharma","nameEN":"Benitec Biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Benitec Biopharma,BNTC,Benitec Biopharma股票,Benitec Biopharma股票老虎,Benitec Biopharma股票老虎国际,Benitec Biopharma行情,Benitec Biopharma股票行情,Benitec Biopharma股价,Benitec Biopharma股市,Benitec Biopharma股票价格,Benitec Biopharma股票交易,Benitec Biopharma股票购买,Benitec Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}